Valneva Stock Under Pressure at €2.40: Down 40% in Three Months, Testing Support
The stock of the Nantes-based vaccine specialist continues to decline mid-morning this Friday, May 8, as the CAC 40 drops 0.83% during the session. Valneva falls 2.08% to €2.40, following a downward trend that has wiped out more than 40% of its value over three months.
Another Session in the Red, Stock at the Bottom of the SBF 120
The stock is among the top five declines in the SBF 120 during the session, ranking 117th out of 120 listed values. The biotech drops 2.08% while the broader index falls 0.79%. Over seven sessions, the stock still shows a gain of 3.76%, indicating an attempt to stabilize after a prolonged fall. The three-month decline remains massive at 40.44%, and the annual performance stands at -18.07%. The session unfolds in a pressured Parisian market, with the European healthcare sector also moving into negative territory, as exemplified by Sanofi dropping 1.26%.
Stock Stalls Between Support at €2.26 and Deteriorating Moving Averages
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The stock is trading in the lower part of its Bollinger Bands, close to the technical support identified at €2.26. This level was already tested during the session on May 4, following the capital increase of 84 million euros completed at the end of April. The RSI at 37 indicates a selling momentum still in place, without reaching the oversold zone. The price remains far from its moving averages: the MM50 at €3.37 and the MM200 at €3.88 confirm a deteriorated trend in the medium and long term. On the agenda, the next key event is the Bernstein European Small & Mid-Cap Conference scheduled for May 21, 2026, before the general assembly on June 1.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 65,8 millions d'euros
Quarterly revenue: 65,8 millions d'euros
Revenue growth: -32,6 %
EBITDA: -39,8 millions d'euros
Net income: -63,3 millions d'euros
Guidance from the release
Malgré l'impact négatif persistant du contexte géopolitique sur les voyages, Valneva a confirmé ses perspectives pour 2026
Risks mentioned
Impact négatif persistant du contexte géopolitique sur les voyages affectant les ventes de produits
Dépendance commerciale élevée envers les livraisons d'IXIARO au Département américain de la Défense avec calendrier incertain
Recentrage stratégique d'IXCHIQ sur les marchés endémiques affectant les perspectives commerciales du vaccin contre le chikungunya
Opportunities identified
Décisions réglementaires attendues pour le candidat vaccin LB6V contre la maladie de Lyme dans les 12 prochains mois
Amélioration attendue des marges brutes au second semestre après impact d'éléments non récurrents au S1 2026
Bénéfices futurs de l'initiative de restructuration visant à réduire la consommation de trésorerie et optimiser les opérations
Outlook / guidance
Expected revenue: 147,5 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
